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Abstract (280 words) 53 
Background: Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk 54 
stratification to identify those for whom Prostate Specific Antigen (PSA) testing is likely to be most valuable. 55 
However, it is unclear if introducing a genetic test influences decisions about the use of PSA tests. The 56 
Procaris project aimed to test the effect on future PSA testing of introducing a genetic test for life-time risk 57 
of prostate cancer in general practice.  58 
 59 
Methods: We performed a cluster randomised controlled trial, with randomisation at the level of general 60 
practices. In intervention practices, men were offered an additional genetic test (based on genotyping 31 61 
risk single nucleotide polymorphisms) to the standard PSA test, informing them about their lifetime genetic 62 
risk of prostate cancer, distinguishing between ‘average’ risk and high risk. The primary outcome was the 63 
proportion of men having a repeated PSA test within two years. A multilevel logistic regression model was 64 
used to test the association. 65 
 66 
Findings: In total, 146 practices participated, 73 in each study arm. In intervention practices 3558 men were 67 
recruited and in control practices 4242. Of the eligible men, 1235 (34.7%) received the genetic test. We 68 
found no significant difference (p=0.53) in the proportion of PSA tests between control and intervention 69 
practices. Men who had a high genetic risk had a higher propensity for repeated PSA test within two years 70 
than men with an average genetic risk (OR = 8.94, p<0.01).  71 
 72 
Interpretation: Providing GPs with access to a genetic test to assess life-time risk of prostate cancer did not 73 
reduce the overall number of future PSA tests. Among men who had a test, knowledge of the genetic risk 74 
significantly influenced future PSA testing.  75 
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Introduction 76 
Prostate cancer is the most common cancer among men in Europe, affecting about 190,000 men for the 77 
first time every year and causing about 80,000 deaths. 1,2 A commonly used method for early detection of 78 
prostate cancer is the Prostate Specific Antigen (PSA) test, although this method has limited accuracy.3 This 79 
results in both failure to detect genuinely aggressive cancers and over-detection and over-treatment of 80 
indolent prostate cancers. Currently, although still debated, population-based screening using the PSA test 81 
is not advised.4,5 Opportunistic screening and testing is increasingly common however, but with the same 82 
uncertain benefits and some risks, including risk of over-diagnosis.6 Therefore, there is interest in whether 83 
PSA testing can be targeted to those for whom it may be more valuable.  84 
 85 
Risk stratification is proposed as a strategy to reduce the overall number of men having the PSA test and to 86 
improve the benefit-to-harm ratio by targeting those most likely to benefit.7 This is already advocated in 87 
guidelines assessing risk by family history.4,8 Now, genetic markers offer potential to improve risk 88 
assessment for developing prostate cancer. So far, scientific advances in genome-wide association studies 89 
have identified more than 100 genetic variants for higher prostate cancer risk, the so-called single 90 
nucleotide polymorphisms (SNPs).9,10 It has been estimated that the currently known risk-SNPs together 91 
explain approximately 33% of the familial risk of prostate cancer in populations of European ancestry, and 92 
that the top 10% of men in the risk distribution have a 2.9-fold increased relative risk of prostate cancer, 93 
compared with the general population.10 Retrospective studies comparing non-genetic risk prediction 94 
models for the detection of prostate cancer with models containing SNP information showed that genetic 95 
models had higher specificity than the non-genetic models based on PSA level, age and family history.11,12  96 
Despite the potential benefits, few studies have used genetic prostate cancer risk assessment in the clinical 97 
setting as a tool for improving use of PSA and diagnosing prostate cancer, particularly in general practice 98 
where most symptoms are presented and testing takes place. It can be hypothesised that the number of 99 
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PSA tests would increase in the small group of men with increased risk and could be reduced in the large 100 
group of men with ’average’ risk.13 101 
 102 
We aimed to test the effect on future PSA testing of introducing a genetic test for life-time risk of prostate 103 
cancer among men with a normal PSA test in general practice.  104 
 105 
Methods 106 
 107 
Study design 108 
We performed a cluster randomised controlled trial with randomisation at the level of general practices. 109 
Block randomisation was applied to balance groups with respect to number of doctors in a practice. The 110 
study follows the CONSORT statement for reporting randomised trials and has been described in detail 111 
previously.13 This study is registered with ClinicalTrials.gov, number NCT01739062. 112 
 113 
Setting and participants 114 
The study took place from February 2013 to November 2014 in Central Region Denmark.  This is one of five 115 
regions in Denmark and has 1.3 million inhabitants and about 850 general practitioners (GPs) in 400 116 
practices. All Danish residents have free access to GPs who serve as gatekeepers to the rest of the health 117 
care system. Over 98% of all citizens are registered with a specific practice. It is mandatory for GPs to use 118 
electronic patient records, and test requisitions and test results are transferred electronically.14 All Danish 119 
citizens have a unique personal identifier number which is registered for all contacts and investigations and 120 
which makes it possible to link all data on individual basis.15 121 
 122 
Men were eligible for participation if they were aged 18-80 years, registered with one of the randomised 123 
practices and had a normal PSA test at inclusion. A normal PSA test was defined as a value below 3.0 ng/ml 124 
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for men below age 60, below 4.0 ng/ml for men aged 60-70, and below 5.0 ng/ml for men aged 70 or 125 
above. Men were excluded if they had an elevated PSA level at inclusion or within the previous two years, 126 
known prostate or bladder disease, or a current or previous prostate cancer diagnosis.  127 
 128 
In this trial, men of non-European ancestry were included but not offered the genetic test, as genetic risk 129 
estimates were based on data from European-descent population studies only (Supplementary file 1). For 130 
safety reasons, men in the intervention group who had more than one close relative with a prostate cancer 131 
diagnosis were advised to undergo systematic screening with PSA tests according to current clinical 132 
guidelines in Denmark.16 Both groups however were still included in the intention-to-treat analysis. The GP 133 
determined eligibility for the genetic test in the clinical setting based on criteria incorporated into the web-134 
based test-ordering system.  135 
 136 
Intervention 137 
In addition to a PSA test, men in intervention practices were offered an additional genetic risk assessment. 138 
Based on genotyping of 31 risk loci/SNPs (Supplementary file 1), individual lifetime prostate cancer risk was 139 
calculated for each man after adjusting for prostate cancer family history 13. Lifetime risk scores were 140 
dichotomised into an ‘average’ risk (<30%) and ‘high’ risk (≥30%) categories, thus conservatively adhering 141 
to the Danish recommendations to screen individuals who (based on family history) have an estimated 33% 142 
lifetime risk of being diagnosed with prostate cancer.16  143 
 144 
The procedure was as follows: when a man was to have a PSA test, and met the inclusion criteria, the GP 145 
informed him about the study and provided written information. If he consented to participate, the GP 146 
drew an additional 4 ml EDTA-stabilized blood sample, which was sent to the laboratory together with an 147 
online request for a genetic risk assessment, including information about the man’s age and family history 148 
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of prostate cancer. Within 2-6 weeks, the laboratory analysed the genetic test and sent the result 149 
electronically to the intervention practice GP, with one of the following recommendations: 150 
 151 
High lifetime risk: 152 
“The patient belongs to a group with increased risk of developing prostate cancer in the future. If the 153 
patient develops prostate cancer in the future, in most cases, the cancer will be slow growing. For early 154 
detection, the patient is encouraged to have a yearly PSA test”.  155 
Average lifetime risk: 156 
“The patient belongs to a group of patients at average lifetime risk of getting a prostate cancer diagnosis. It 157 
is not considered necessary or beneficial for the patient to have more PSA tests in the future, unless the 158 
patient develops urinary tract symptoms or one or more of his relatives develops prostate cancer”.  159 
 160 
If the risk assessments could not be performed because family history was unclear or unknown, a risk 161 
estimate was provided, doubling the risk of someone with “no relatives with prostate cancer”. If this 162 
estimate was >30%, the patient was advised to enter a screening program and received the following 163 
advice: “The risk for developing prostate cancer in the future cannot be estimated due to missing 164 
information for family history. However, the patient may benefit from a screening program with PSA tests, 165 
with a view to early diagnosis”. 166 
 167 
Once the practice received the genetic risk assessment results, the GP or other practice personnel informed 168 
the patient about the result. In case of questions, both intervention practice personnel and men could 169 
contact a project telephone hotline to the researchers. Each intervention practice also received written 170 
information with recommendations about follow-up PSA testing according to current guidelines and 171 
information about the benefits and shortcomings of genetic risk assessment as a tool to support decision-172 
making about PSA-testing for prostate cancer.  173 
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 174 
The GPs were remunerated with an additional 142 Danish krone (≈ €19) per consultation, which covered 175 
the additional work in relation to information and blood sampling. Control practices performed care as 176 
usual and received no further information or compensation. The initial intervention period ran from 177 
February 2013 until December 2013. However, because the GPs appreciated the opportunity to offer the 178 
genetic test, it was made available for them to include men for another year until November 2014. We 179 
used the full period (February 2013 - November 2014) for our analyses. 180 
 181 
Outcomes 182 
The primary outcome was the proportion of men who had a PSA test within two years after a normal PSA 183 
test result at inclusion. Two years of follow-up was chosen as this was considered a reasonable screening 184 
interval for healthy adults.17 Although men were included only through GP practices, tests requested by 185 
hospitals and private specialist clinics were also taken into account as a PSA test in the follow-up period.  186 
 187 
Secondary outcomes were the proportion of men with an elevated PSA test and the proportion of men 188 
referred for prostate biopsies. Data about the date and level of the PSA test were collected from the 189 
regional clinical laboratory information system (LABKA), which keeps results for all PSA tests in the region. 190 
Prostate biopsies were identified in the Danish National Patient Register.18 191 
 192 
Participant characteristics 193 
Information on age, marital status (married, widower, divorced, and never married), highest achieved 194 
education (<10 years (primary and lower secondary school), 10–12 years (upper secondary school or 195 
vocational training), >12 years (higher education)), household income adjusted for number of persons in 196 
the household (in tertiles), and working status (employed, unemployed, pensioner, or other) was collected 197 
from registries at Statistics Denmark.19,20  198 
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 199 
Practice characteristics 200 
To account for possible differences between practices at baseline, we calculated per practice the number of 201 
PSA tests per 1000 men aged >40 years in the year before the intervention started (2012).  202 
 203 
Sample size 204 
We expected that 75% of the men in the intervention group would receive the genetic prostate cancer risk 205 
assessment, and we estimated that 88% of the men would have an average genetic risk. The sample size 206 
was based on an expected reduction of PSA test by 50% in the group with an average genetic risk.13 This 207 
would result in a reduction from 23% to 15% in the overall proportion of men with a PSA test in the follow-208 
up period. This required the inclusion of 1244 men in the intervention arm and, allowing for a design effect 209 
(intra class correlation) of 1.2, provided study power of 90% with alpha of 5%.  210 
 211 
Statistical analysis 212 
Data were analysed using Stata (release 14). For all statistical tests, two-sided hypothesis testing with an 213 
alpha of 0.05 was applied. Primary analyses were based on an ‘intention-to-treat’ principle for both primary 214 
and secondary outcomes.  215 
 216 
A logistic multilevel model with men nested within practices was used to estimate odds ratio (OR) as the 217 
association between exposure (being in an intervention practice) and outcome. In addition, we performed 218 
a time-to-event analysis using a Cox proportional hazards regression model to include the differences in 219 
time to the PSA test.  220 
 221 
Analyses were adjusted for participant characteristics (age, education and household income) and for the 222 
number of PSA tests per 1000 men aged >40 years per practice at baseline. Missing values on background 223 
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characteristics (500 cases, 6.4%) were imputed using a multiple imputation procedure based on the ‘MICE’ 224 
approach.21  225 
 226 
Sub-group analyses were performed on men in intervention practices, comparing men with and without a 227 
genetic test and on men with a genetic test comparing men with a high-risk genetic profile to men with a 228 
normal lifetime risk in relation to outcomes.  229 
 230 
To study the difference in uptake of the intervention, we calculated the actual intra class correlation (ICC) 231 
for the chance of receiving a genetic test. 232 
 233 
Men who died of non-prostate cancer related causes or moved within the follow-up period of two years 234 
were excluded from the analysis.  235 
 236 
Ethical approval and considerations 237 
The study was conducted according to the Helsinki Declaration principles. It has been notified to the Danish 238 
Data Protection Agency (Journal no. 2011–41–6904) and collection of data was handled according to their 239 
guidelines. The study has obtained permission from the Danish Scientific-Ethical Committee (Journal no. 1-240 
10-72-43-12).  241 
 242 
All participants provided informed consent. Men in the intervention group received printed information 243 
from the GP and could withdraw from the study at any time and have their blood sample destroyed and 244 
project data deleted.  245 
 246 
Results 247 
 248 
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Study population 249 
After excluding practices (n=9) that were used for an initial pilot to set-up to test the project infrastructure, 250 
146 (36.5% of total) practices in the region accepted the invitation to participate and were randomised 251 
(Figure 1).  252 
 253 
In the intervention period, 5836 men in the intervention practices and 6750 men in the control practices 254 
received at least one PSA test (Figure 1). After applying the exclusion criteria, 7800 eligible men were 255 
included in the analyses (intervention, n=3558; control, n=4242).  256 
Figure 1. Flowchart 257 
Men who received a PSA test were similar between intervention and control practices on education, 258 
income, marital status, and working status (Table 1). In intervention practices, fewer men aged <55 (22.9% 259 
versus 27.1%) and more men aged >69 years (25.6% versus 21.6%) were eligible for inclusion. Intervention 260 
practices had on average slightly more men aged >40 years in their practices than control practices (means 261 
714.4 and 676.0, respectively) and performed fewer PSA tests per 1000 men per year at baseline (86.5 262 
versus 104.7).   263 
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Table 1. Description of practice and participant sample at baseline 264 
 Control 
(n=4242) 
Intervention 
 Total 
(n=7800) 
Total 
Intervention 
(n=3558)  
Received 
genetic test 
(n=1235) 
Did not 
receive 
genetic test 
(n=2323) 
Δa  
Cluster level (GP practices)       
Average number of men age >40 per 
practice (SD) 
676.0  
(412.5) 
714.4  
(387.1) 
   695.3 
(398.9) 
Number of PSA tests per 1000 men age 
>40 at baseline (SD) 
104.7  
(95.8) 
86.5  
(67.5) 
   95.5  
(82.9) 
Number of practices 73 73    146 
       
Individual level (men)       
Age (%)     *  
 ≤54 27.1 22.9 25.4 21.5  25.2 
 55-59 13.9 13.3 15.0 12.4  13.6 
 60-64 17.5 17.1 19.0 16.1  17.3 
 65-69 19.9 21.1 19.1 22.1  20.4 
 70≥ 21.6 25.6 21.4 27.9  23.5 
Highest educational level (%)      *  
 <10 yrs (primary and lower 
secondary school) 
28.2 28.1 23.1 30.9  28.1 
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 10–12 yrs (upper secondary school 
or vocational training) 
51.8 51.2 53.0 50.2  51.5 
 >12 yrs (higher education) 20.0 20.7 23.9 18.9  20.3 
Household income (tertiles, %)     *  
 Low 33.8 32.8 24.8 37.1  33.4 
 Medium 33.2 33.5 35.5 32.4  33.4 
 High 33.0 33.7 39.7 30.5  33.2 
Marital status (%)     *  
 Married 72.1 74.4 78.9 72.0  73.1 
 Widower 3.6 3.3 2.5 3.8  3.5 
 Divorced 10.7 10.5 8.7 11.5  10.6 
 Never married 13.6 11.8 9.9 12.7  12.8 
Working status (%)     *  
 Employed 51.5 51.4 58.5 47.6  51.4 
 Unemployed 2.2 1.7 1.3 1.8  2.0 
 Pensioner 42.8 44.0 37.6 47.5  43.4 
 Other 3.5 2.9 2.6 3.1  3.2 
a Intervention group only: received genetic test versus did not receive test (chi-square test) 265 
* p<0.01 266 
 267 
  268 
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Genetic test 269 
Out of the 3558 eligible men in intervention practices, 1235 (34.7%) received a genetic test (Figure 1). This 270 
percentage ranged from 0% to 82% between practices (intra-class correlation coefficient (ICC) = 0.37). Men 271 
who received the genetic test were younger (p<0.01), more highly educated (p<0.01), more often married 272 
(p<0.01) and employed (p<0.01) and had higher incomes (p<0.01) than men who did not receive the 273 
genetic test (Table 1).   274 
 275 
Of the men who received a genetic test, 1047 (84.8%) had an average genetic risk for prostate cancer and 276 
136 (11.0%) had a high risk (Table 2). For 52 men (4.2%) the genetic risk could not be calculated or was not 277 
traceable in the registries. In further analyses they are included as a separate category ‘Unknown risk’.  278 
 279 
Effect of genetic test on future PSA tests 280 
Two years after inclusion, a total of 1218 men (34.2%) in the intervention practices and 1628 (38.4%) men 281 
in the control practices had a PSA test (OR = 0.95, 95% CI=0.78-1.14, p=0.56) (Table 2). In the intervention 282 
group, men with an average genetic risk (24.9%) had fewer PSA tests than men without a genetic test 283 
(37.5%; OR = 0.65, 95% CI=0.54-0.78, p<0.01) while men with a high genetic risk had more (75.0%; OR = 284 
5.96, 95% CI=3.96-8.97, p<0.01). 285 
 286 
The proportion of PSA tests that resulted in an elevated value was similar between the control and 287 
intervention group (2.3% vs 2.2%) (OR = 1.01, 95% CI=0.71-1.43, p=0.96). Higher percentages were found in 288 
the group with a high genetic risk (6.6%) than in men without a genetic test (2.2%) (OR = 3.31, 95% CI=1.57-289 
6.97, p<0.01).  290 
 291 
In the subgroup of men that had a PSA test in the follow-up period, 6.2% of those tests were elevated (not 292 
shown). This was similar between intervention (6.4%, 78/1218) and control (6.0%, 97/1628) practices (OR = 293 
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1.08, p=0.62). No significant difference was found between men with a high genetic risk (8.8%, 9/102) and 294 
men with an average genetic risk (6.1%; 16/261, OR = 1.49, p=0.36). 295 
 296 
No difference between control and intervention was found on the numbers of biopsies (both 0.2%). 297 
 298 
  299 
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Table 2. Unadjusted primary and secondary outcomes after two years follow-up  300 
 Control 
(n=4242) 
Intervention 
(n=3558) 
OR a  
(95% CI, sign.) 
 
Intervention  
No genetic 
test 
(n=2323) 
Average 
genetic risk 
(n=1047) 
High  
genetic risk 
(n=136) 
OR b 
(95% CI) 
OR c  
(95% CI) 
Men with a 
PSA test, N 
(%) 
1628 
(38.4%) 
1218  
(34.2%) 
0.95  
(95% CI=0.78-
1.14) 
833 
(37.5%) 
261 
(24.9%) 
102 
(75.0%) 
0.65  
(95% CI=0.54-
0.78) 
5.96 
(95% CI=3.96-
8.97) 
Men with an 
Elevated 
PSA test, N 
(%) 
97 
(2.3%) 
78 
(2.2%) 
1.01  
(95% CI=0.71-
1.43) 
50 
(2.2%) 
16 
(1.5%) 
9 
(6.6%) 
0.71 
(95% CI=0.40-
1.26) 
3.31 
(95% CI=1.57-
6.97) 
a Control vs. intervention, b Average risk vs. no genetic test, c High risk vs. no genetic test 301 
 302 
Adjusted analysis 303 
After adjusting for confounders, no significant effect was found of the intervention on the number men 304 
with a PSA test at two years follow-up (OR = 0.95, p=0.53) (Table 3). The number of PSA tests per 1000 men 305 
aged >40 per practice at baseline (OR = 1.02, p<0.01 per 10 extra tests), older age (increasing OR per age 306 
group), and a high income (OR = 1.28, p<0.01 compared to the low-income group) were associated with a 307 
higher chance of a future PSA test (Table 3).  308 
 309 
The time-to-event (i.e. time to repeated PSA test) analysis showed no significant difference between 310 
control and intervention practices (p=0.36). However, for those men who had  a PSA test, this was done on 311 
average 21 days later in intervention practices than in control practices (483 days, (SD=188) versus 462 312 
(SD=178)) (p=0.01) (not in table).  313 
 314 
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Within intervention practices, men with an average genetic risk had a significantly lower chance of having a 315 
future PSA test than men who did not receive the genetic test (OR = 0.62, p<0.01), while men with a high 316 
genetic risk had a significantly higher chance (OR = 8.94, p<0.01) (Table 3) and the difference between men 317 
with an average and high genetic risk was also statistically significant (OR = 14.51, p<0.01) (not in table).  318 
 319 
The number of PSA tests with an elevated value followed the same pattern; no significant difference was 320 
found between intervention and control practices (OR = 1.08, p=0.65). 321 
 322 
  323 
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Table 3. Primary and secondary outcomes after 2 years follow-up; adjusted multilevel logistic regression 324 
model (OR) 325 
 Men with a PSA tests Men with an elevated PSA tests 
 Total 
population 
(n=7800) 
Intervention 
group only 
(n=3558) 
Total 
population 
(n=7800) 
Intervention 
group only 
(n=3558) 
Cluster level (practices)     
Intervention (ref = control) 0.95  1.08  
Number of PSA tests per 1000 men age 
>40 at baseline (x10) 
1.02** 1.02** 1.02** 1.03* 
     
Individual level (men)     
Genetic test result (ref = No genetic test)     
 Average risk  0.62**  0.64 
 High risk  8.94**  4.06** 
 Unknown risk  2.46*  3.41 
     
Age (ref ≤54)     
 55-59 1.98** 2.11** 3.12** 2.12 
 60-64 2.59** 2.56** 3.94** 2.60* 
 65-69 3.41** 3.31** 3.92** 3.01** 
 70≥ 4.01** 4.17** 4.56** 3.04** 
Highest educational level (ref <10 yrs)     
20 
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 10–12 yrs (upper secondary school or 
vocational training) 
1.12 1.07 1.19 1.23 
 >12 yrs (higher education) 1.10 1.09 1.25 1.63 
Household income (ref = low)     
 Medium 1.07 1.31** 1.37 2.18* 
 High 1.28** 1.50** 1.40 1.96 
* p<0.05 ** p<0.01 326 
 327 
  328 
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Discussion 329 
Main findings 330 
The introduction of the genetic risk assessment in general practice did not affect the overall number of men 331 
with a normal PSA test receiving a future PSA test within two years. Uptake of the genetic test was about 332 
one third and within this group, more men with a high lifetime prostate cancer risk had a further PSA test 333 
compared with men at an average lifetime risk.  Men with an average lifetime risk also had fewer PSA tests 334 
compared to men who did not receive the genetic test.  335 
 336 
Strengths and weaknesses  337 
Using routinely collected data from registries linked with the personal identifier number ensured complete 338 
follow-up and allowed us to use all initially included men in the analyses. The follow-up period of two years 339 
was not long enough to draw final conclusions about the effect of this intervention on the diagnosis or 340 
mortality rate of prostate cancer.  341 
 342 
The study was conducted in routine practice and with limited support to the GPs. Selection bias was 343 
evident for the limited proportion of eligible men who received the genetic test, whether by GPs and/or the 344 
men consulting, resulting in a relatively young and high income sub-sample offered and accepting the test. 345 
This may, for example, have comprised men who were more responsive to the information about lifetime 346 
risk. Our study does not provide information about the selection mechanism behind the low uptake. It may 347 
be more due to low uptake among some GPs (ICC between practices of 0.37, range of uptake from 0-82%) 348 
rather than participant influences. However, the intention-to-treat analysis minimised this selection bias 349 
concerning the primary outcome analysis.  350 
 351 
Comparison with other studies 352 
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Until now, a genetic test to assess the risk for prostate cancer has not been tested in a GP setting and thus 353 
no direct comparisons can be made. The Stockholm-1 cohort study tested whether a genetic model based 354 
on 36 SNPs could reduce the number of biopsies compared to a non-genetic model based on age, PSA, free-355 
to-total PSA, and family history.11 Their genetic model reduced the number of biopsies more than the non-356 
genetic model. The proportion of men with an elevated follow-up PSA level in our study population is 357 
consistent with downstream effects in previous studies. 6,22 The association that we found between the 358 
genetic test result and the number of elevated follow-up PSA tests for those at high risk, and reduced tests 359 
for those at average risk, illustrates the potential for downstream effect of the intervention. Given the 360 
relatively low levels of implementation, however, overall downstream effects were not shown in this study 361 
in terms of referrals for prostate biopsy.  362 
 363 
It is a complex decision whether to have a PSA test, but studies on decision aids have shown that better 364 
informed decisions can result in fewer men receiving PSA tests.23,24 We do not know how the GPs used the 365 
test results and how they conveyed the result to the men, but other studies suggest that genetic risk 366 
assessment increases clinicians’ confidence in managing familial cancer.25 Recent studies show that both 367 
men and GPs still struggle with PSA screening. 6,26–29 In a study among men who had had direct-to-368 
consumer genome-wide profiling to assess prostate cancer risk, Bloss et al. found that men had a 20% 369 
higher intention to take PSA tests with a high lifetime risk.30 We found that 75% of the men with a high risk 370 
actually had a test performed within two years, suggesting that men have acted on such knowledge 371 
(although the GP may also have influenced such decisions quite significantly) and there is potential for risk 372 
stratification to assist routine practice. 373 
 374 
Implications for practice 375 
Implementing the test in routine practice, we did not find an effect on future PSA testing for all men in the 376 
intervention practices as a whole. It is important to gain insight into the process of implementation. If 377 
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uptake continues to be low for either GP or participant reasons, there will be no impact of such risk 378 
stratification at population level, even if there are significant effects in sub-groups. However, if barriers to 379 
implementation can be removed, further evaluations may show a similar more appropriate targeting of PSA 380 
testing to those at high risk, and perhaps an overall reduction of testing. It is important to identify the 381 
barriers, address them, and to reach a firm conclusion whether or not to make a genetic test for life time 382 
risk of prostate cancer available in general practice. 383 
 384 
Further research 385 
This study showed that it is feasible to integrate a genetic prostate cancer risk assessment in a general 386 
practice setting. So far, this has not resulted in an overall reduction in the number of future PSA tests. 387 
However, the differences in numbers of future PSA tests between normal and high lifetime risk groups in 388 
those taking up the test suggests that further study is indicated as to whether these effects are replicated, 389 
sustained, and large enough to affect an important range of health services research outcomes such as 390 
quality-of-life, referrals, biopsies, diagnoses of prostate cancer, mortality, impact on over-diagnosis (of 391 
indolent pathologies) and resource use effects. Further research is also necessary to explore factors that 392 
facilitate or hinder implementation of providing this genetic test to men, and how it is used by men (and 393 
family members) in deciding on future screening or testing intentions. Based on this, future interventions 394 
could be developed that support GPs with the integration of genetic tests in routine practice and men with 395 
making informed decisions.  396 
 397 
Conclusion 398 
Offering a genetic test to assess men’s life-time risk of prostate cancer did not reduce the overall 399 
propensity of repeated PSA tests within a two year period among men with a normal PSA. However, 400 
knowledge of genetic risk reduced the number of PSA tests among those at average risk and increased the 401 
number of PSA tests among those at high risk. Further research is needed to examine how uptake of the 402 
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test can be supported and whether such an increase can effectively reduce the number of overall future 403 
PSA tests and the consequent downstream effects.  404 
 405 
 406 
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